Xilio Therapeutics (XLO) Profit After Tax Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | 28.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.16% |
| Dec 31, 2025 | 179.13% |
| Sep 30, 2025 | -16.17% |
| Jun 30, 2025 | -13.78% |
| Mar 31, 2025 | 22.89% |
| Dec 31, 2024 | 25.84% |
| Sep 30, 2024 | 16.29% |
| Jun 30, 2024 | 28.05% |
| Mar 31, 2024 | 23.88% |
| Dec 31, 2023 | 21.34% |
| Sep 30, 2023 | 15.37% |
| Jun 30, 2023 | 21.36% |
| Mar 31, 2023 | -5.84% |
| Dec 31, 2022 | -13.92% |
| Sep 30, 2022 | -21.78% |
| Jun 30, 2022 | -6.18% |
| Mar 31, 2022 | -28.12% |
| Dec 31, 2021 | 5.16% |
| Sep 30, 2021 | -9.66% |